Buy & Sell Brown-Forman Corporation Class B (BF.B) – Brown-Forman Corporation Class B Price Today
Aura AI Summary
Key Stats
- -Market Cap
- Consumer StaplesSector
- -18.64%3M Drawdown
- -Enterprise Value
- -Dividend Yield
- 50 daysTypical Hold Time
Over the past 52 weeks, Brown-Forman Corporation Class B has traded between a low of $22.8 and a high of $31.26, highlighting its annual price range. Over the past three months, Brown-Forman Corporation Class B has recorded a drawdown of -18.64%, reflecting recent price volatility. On average, investors hold Brown-Forman Corporation Class B for approximately 50 days, indicating typical investor behavior on the platform.
About Brown-Forman Corporation Class B
Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.
Most Recent News
Lemonade launches affordable renters insurance in North Dakota starting at $5/month
Lemonade, a tech-driven insurance company, has expanded its renters insurance to North Dakota, offering fast, affordable coverage starting at $5 per month. The service allows renters to manage policies and claims via an app, with about 40% of claims ...
Momentus boosts cash to $76M, advances Vigoride 7 space mission, stock rebounds.
Momentus strengthened its financial position by raising cash to about $76 million through a fully utilized $50 million at-the-market program, a $25 million private placement, and warrant exercises. The company reported progress on its Vigoride 7 miss...
DBV Technologies revises participation at Goldman Sachs Global Healthcare Conference due to CEO travel issue.
DBV Technologies announced a change in its participation at the 47th Annual Global Healthcare Conference by Goldman Sachs, held on June 9, 2026, in Miami. The company's CEO, Daniel Tassé, will not attend the informal discussion as initially planned d...